BNT116 + DTX shows encouraging antitumor activity, consistent induction of immune responses, a manageable safety profile, and no signs of additive toxicity. Updated safety and clinical activity data will be presented along with additional biomarker data.
"BNT116 alone or in combination with either docetaxel or the PD-1 inhibitor cemiplimab (Libtayo ® ) may have synergistic anti-tumor effects, thus potentially addressing the unmet medical need of these cancer patients. The first patient was dosed in JUL 2022, with enrolment expected for approximately 12 months. The study was approved by IRB/IEC, approval numbers: 2022-03/1691 (Turkey), OGYÉI/6962-9/2022 (Hungary), and US and Spain (approval numbers for the later were not provided)."
P1 | "BNT116 alone or in combination with either docetaxel or the PD-1 inhibitor cemiplimab (Libtayo®) may have synergistic anti-tumor effects, thus potentially addressing the unmet medical need of these cancer patients. Secondary endpoints are related to clinical activity, i.e., tumor assessments, as per RECIST 1.1. The first patient is planned to be dosed in May 2022, with enrolment expected for approximately 12 months."